Monograph Details
|
|
Hematology
> Bleeding disorders
|
|
FEIBA VH |
| Manufacturer |
|
Baxter |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hemostatic. |
| Generic Name |
|
Anti-inhibitor Coagulant Complex (AICC) 500 units, 1000 units, 2500 units; per vial; for IV infusion after reconstitution; contains Factors II, IX, X (non-activated); Factor VII (activated); Factor VIII inhibitor bypassing activity; Prothrombin Complex Factors; heparin-free. |
| Indications |
|
To control spontaneous bleeding or to cover surgical interventions in Hemophilia A and B with inhibitors (see literature). |
| Adults and Children |
|
Infusion rate: ≤2units/kg per minute. Joint hemorrhage: 50units/kg every 12hrs; may increase to 100units/kg. Mucous membrane bleeding: 50units/kg every 6hrs; if bleeding continues, increase to 100units/kg every 6hrs; max: 2 doses. Soft tissue: 100units/kg every 12hrs. Other severe hemorrhages (eg. CNS bleeding): 100units/kg every 12hrs; may increase to 6hr intervals. All: Max 200units/kg per day (100units/kg per dose). |
| Contraindications |
|
Normal coagulation mechanism. |
| Precautions |
|
Not for treating bleeding episodes due to coagulation factor deficiencies; must have circulating inhibitors to one or more coagulation factors. Disseminated intravascular coagulation (DIC); fibrinolysis: not recommended. Monitor for development of DIC and/or acute coronary ischemia; discontinue if occurs. Contains human plasma; monitor for possible infection transmission. Non-hemophiliacs. Latex allergy. Newborns. Pregnancy (Cat.C). |
| Interactions |
|
Separate antifibrinolytics by 12 hours. |
| Adverse Reactions |
|
Allergic reactions, thromboembolic events, DIC; rare: myocardial infarction. |
| Extra Text |
|
Note: Report all infections suspected to be transmitted by Feiba VH to (800) 423-2862. |
| How Supplied |
|
Single-dose vials—1 (w. diluent, transfer device) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
